Detalles de la búsqueda
1.
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Mol Cancer
; 23(1): 115, 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38811992
2.
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(9): 1275-1289, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34363762
3.
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Lancet Oncol
; 22(7): 1034-1046, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34143970
4.
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
MAbs
; 13(1): 1857100, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33397194
5.
Development of PARP and Immune-Checkpoint Inhibitor Combinations.
Cancer Res
; 78(24): 6717-6725, 2018 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30498083
6.
IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells.
Blood Adv
; 1(10): 577-589, 2017 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29296700
Resultados
1 -
6
de 6
1
Próxima >
>>